Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 15/20 | 0.58 |
| ▸ | TLR2 | O60603 | 1/20 | 0.58 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.58 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299161 | 0.85 | ERN1 (0.58) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL4898660 | 0.82 | ALDH1A1 (0.50) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL1527154 | 0.82 | ERN1 (0.69) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL19025079 | 0.81 | ERN1 (0.51) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL3658867 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL4011543 | 0.79 | ALDH1A1 (0.47) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL29683824 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL29628664 | 0.79 | ALDH1A1 (0.47) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL6202266 | 0.79 | ALDH1A1 (0.47) | ERN1TLR2TLR1TLR6ALDH1A1 | |
| SCHEMBL5645697 | 0.79 | ERN1 (0.59) | ERN1TLR2TLR1TLR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-04 | — | — | US | disclosed |
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| EP-3728267-B1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RES OICR (CA) | 2023-09-13 | — | — | EP | disclosed |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-29 | — | — | US | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-02-08 | — | — | US | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2021-02-25 | — | — | US | disclosed |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-14 | — | — | US | disclosed |
| WO-2015163485-A1 | ISOINDOLINE-1-ONE DERIVATIVES AS CHOLINERGIC MUSCARINIC M1 RECEPTOR POSITIVE ALLOESTERIC MODULATOR ACTIVITY FOR THE TREATMENT OF ALZHEIMERS DISEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-29 | — | — | WO | disclosed |
| US-4728662-A | DIURETICS, URICOSURICS, HYPOTENSIVES | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0119294-B1 | BENZISOXAZOLE CARBOXYLIC ACIDS | ABBOTT LABORATORIES (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4673746-A | DIURETICS, HYPOTENSIVES | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1987-06-16 | — | — | US | disclosed |
| US-4490384-A | DIURETICS; HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0119294-A1 | Benzisoxazole carboxylic acids | ABBOTT LABORATORIES (US) | 1984-09-26 | — | — | EP | disclosed |
| WO-1984003199-A1 | BENZISOXAZOLE CARBOXYLIC ACIDS | ABBOTT LAB (US) | 1984-08-30 | — | — | WO | disclosed |
| US-4456612-A | DIURETICS | ABBOTT LABORATORIES (US) | 1984-06-26 | — | — | US | disclosed |
| EP-0002666-B1 | 1,2-BENZISOXAZOLYLOXY (OR THIO) ACETIC ACIDS AND RELATED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-02-17 | — | — | EP | disclosed |
| EP-0002666-A1 | 1,2-Benzisoxazolyloxy (or thio) acetic acids and related compounds, process for their preparation and medicines containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | ERN1 3256/4885TLR2 2150/4885TLR1 795/4885 |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | ERN1 2839/4885TLR2 1565/4885TLR1 674/4885 |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | ERN1 3256/4885TLR2 2150/4885TLR1 795/4885 |
| US-20210009572-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRNA5 | ERN1 3869/4885TLR2 1815/4885TLR1 1147/4885 |
| US-20210053978-A1 | TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF | BCL6, BCL6B, BCL3 | ERN1 1036/4885TLR2 4336/4885TLR1 3579/4885 |
| US-11242351-B2 | Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof | BCL6, BCL6B, BCL3 | ERN1 1036/4885TLR2 4336/4885TLR1 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.